Skip to content

Lipocine validates trial with positive top line results

June 20, 2017

Lipocine validates “no titration” dosing regimen with positive topline efficacy results for lpcn 1021, oral testosterone candidate

* Lipocine Inc- LPCN 1021 achieved primary endpoints confirming efficacy of twice daily oral administration

* Lipocine Inc- LPCN 1021 generally met pre-specified per dose secondary endpoints for twice daily oral administration

* Lipocine Inc- new drug application resubmission planned in Q3 of 2017

* Lipocine Inc – all drug related adverse events (“AES”) were either mild or moderate in intensity and none were severe

http://reut.rs/2rND9ym

Advertisements

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: